ADC 1013

Drug Profile

ADC 1013

Alternative Names: ADC-1013; ADC-1013 (agonistic immunostimulatory antibody); JNJ 7107; JNJ-64457107

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alligator Bioscience
  • Developer Alligator Bioscience; Janssen Biotech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD40 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 08 Jan 2018 Alligator Bioscience plans a clinical trial (Combination therapy) and a phase II trial in Cancer
  • 07 Nov 2017 Efficacy and safety data from a phase I trial in Solid tumours released by Alligator Bioscience
  • 08 Mar 2017 Alligator Bioscience completes a phase I trial in Solid tumours (Late-stage disease) in Sweden, Denmark (Intratumoural) (NCT02379741)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top